Annovis Bio, Inc. (ANVS) is a publicly traded Healthcare sector company. As of August 25, 2026, ANVS trades at $1.79 with a market cap of $77.54M and a P/E ratio of -1.25. ANVS moved +2.29% today. Year to date, ANVS is -49.42%; over the trailing twelve months it is -26.16%. Its 52-week range spans $1.11 to $5.60. Analyst consensus is strong buy with an average price target of $11.00. Rallies surfaces ANVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks ANVS insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $1.79 |
| Market Cap | $77.54M |
| P/E Ratio | -1.25 |
| EPS | $-1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.60 |
| 52-Week Low | $1.11 |
| Volume | 247 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-28.85M |
| Gross Margin | 0.00% |
3 analysts cover ANVS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.00.